Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celljuvant Study of High-Dose MF59-Adjuvanted Quadrivalent Cell-Derived Influenza Vaccine in Adults ≥50 Years
2023-503763-42-00Phase 3Completed
- Sponsor
- CSL Seqirus
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
Phase 3, randomised, single-blind trial of aQIVc HD in influenza (3 arms), sponsored by CSL Seqirus. Primary endpoints: Lot-to-lot immunogenicity consistency of aQIVc HD and Immunogenicity of aQIVc HD vs QIVr and aQIV. Started Sep 2023; status: completed.
02
Drugs
aQIVc HD
03
Conditions
influenza
Beyond the preview
Go deeper on 2023-503763-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503763-42-00.